Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22915324 | 0.85 | FFAR2 (0.32) | — | |
| SCHEMBL25662649 | 0.84 | MMP1 (0.35) | MMP1MMP9MMP14 | |
| SCHEMBL22561303 | 0.84 | MMP1 (0.35) | MMP1MMP9MMP14 | |
| SCHEMBL30408938 | 0.84 | MMP1 (0.35) | MMP1MMP9MMP14 | |
| SCHEMBL19522520 | 0.84 | MMP1 (0.35) | MMP1MMP9MMP14 | |
| SCHEMBL20222906 | 0.83 | MMP9 (0.30) | MMP9 | |
| SCHEMBL16410993 | 0.82 | MMP1 (0.34) | MMP1MMP9MMP14 | |
| SCHEMBL26082867 | 0.81 | MMP1 (0.33) | MMP1MMP9MMP14 | |
| SCHEMBL20902060 | 0.79 | CTSS (0.39) | MMP1MMP9MMP14 | |
| Trifluoroacetic Acid SCHEMBL30409438 | 0.78 | MMP1 (0.33) | MMP1MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | SDCBP, DDOST, KRTCAP2 | MMP1 3965/4885MMP9 4122/4885MMP14 3733/4885 |
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | MMP1 1975/4885MMP9 3348/4885MMP14 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.